» Articles » PMID: 2419443

Identification of Histamine Releasing Factor(s) in the Late Phase of Cutaneous IgE-mediated Reactions

Overview
Journal J Immunol
Date 1986 Apr 1
PMID 2419443
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

We have shown that fluids collected from antigen-challenged skin blisters during the late phase reaction cause the release of substantial amounts of histamine (means = 42%, n = 14) from human basophils in vitro. Control fluids collected either during the immediate phase or from an unchallenged blister released less than or equal to 10% histamine from both basophils and lung mast cells. Late phase blister fluids induced low levels of histamine release from human lung cells (means = 11%, n = 4) that were slightly but not significantly greater than levels induced by control blister fluids. The characteristics of basophil release were similar to IgE-mediated stimuli in dose dependence, calcium and temperature requirements, and kinetics. The IgE dependence of the late phase blister fluid was demonstrated by desensitization of the basophils to anti-IgE, which obviated the response to anti-IgE and blister fluid but did not affect a non-IgE-mediated stimulus. Removal of the cell surface IgE with lactic acid also abolished the response to both anti-IgE and late phase blister fluid. Incubation of the "stripped" cells with serum containing IgE myeloma restored the response to anti-IgE but failed to affect response to late phase blister fluid. The characteristics of release obtained with this factor closely resemble those of an IgE-dependent histamine releasing factor from cultured macrophages previously described by our group.

Citing Articles

PEGylation improves the therapeutic potential of dimerized translationally controlled tumor protein blocking peptide in ovalbumin-induced mouse model of airway inflammation.

Seo H, Bae H, Pyun H, Kim B, Lee S, Song J Drug Deliv. 2022; 29(1):2320-2329.

PMID: 35850571 PMC: 9302014. DOI: 10.1080/10717544.2022.2100511.


Blockade of translationally controlled tumor protein attenuated the aggressiveness of fibroblast-like synoviocytes and ameliorated collagen-induced arthritis.

Kim M, Choe Y, Lee H, Jeon M, Park J, Noh H Exp Mol Med. 2021; 53(1):67-80.

PMID: 33408335 PMC: 8080778. DOI: 10.1038/s12276-020-00546-y.


Histamine-releasing factor enhances food allergy.

Ando T, Kashiwakura J, Itoh-Nagato N, Yamashita H, Baba M, Kawakami Y J Clin Invest. 2017; 127(12):4541-4553.

PMID: 29130935 PMC: 5707161. DOI: 10.1172/JCI96525.


Histamine-releasing factor: a promising therapeutic target for food allergy.

Wills-Karp M J Clin Invest. 2017; 127(12):4238-4241.

PMID: 29130933 PMC: 5707146. DOI: 10.1172/JCI98297.


From IgE to Omalizumab.

Kawakami T, Blank U J Immunol. 2016; 197(11):4187-4192.

PMID: 27864548 PMC: 5123831. DOI: 10.4049/jimmunol.1601476.